ADVENT-AML Phase 1B clinical trial update 15 May 2025 Two of three evaluable patients have achieved CRi – Complete Response with incomplete blood count recovery (remission) in Acute Myeloid Leukemia (AML) This clinical trial is designed to enroll 20 newly diagnosed AML patients who are not eligible for chemotherapy or allogeneic stem cell transplant. Known as ADVENT-AML, the trial combines standard of care AML treatment with CHM’s CORE NK technology to test a novel and potentially transformative new paradigm for AML patients ADVENT-AML is the first frontline AML trial to incorporate a cell therapy
CHM Price at posting:
0.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)